Over the past decade, clinical trials for good-performance status patients with unresectable stage III non-small cell lung cancer have shown that concurrent chemoradiation therapy (chemoRT) provides improved survival over sequential chemoradiation therapy. The available data suggest that induction chemotherapy preceding concurrent chemoRT does not further improve survival. Much remains to be learned about optimizing concurrent chemoRT in this setting, including identifying doses and schedules of chemotherapy that can maintain efficacy and reduce toxicity, as well determining optimal RT doses.

中文翻译：

---

局部晚期非小细胞肺癌的治疗：过去十年我们学到了什么，还没有学到什么。

在过去的十年中，针对无法切除的III期非小细胞肺癌的良好状态患者的临床试验表明，同步放化疗（chemoRT）较顺序放化疗具有更高的生存率。现有数据表明，同步化疗之前的诱导化疗不能进一步提高生存率。在这种情况下优化同时进行的化学放疗尚需学习许多知识，包括确定可维持疗效和降低毒性的化疗剂量和方案，以及确定最佳放疗剂量。